News | Amgen
Amgen Foundation Awards and Accolades How We Operate
FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST …
May 16, 2024 · Amgen remains committed to progressing multiple BiTE molecules across a broad range of hematologic and solid tumor malignancies, paving the way for additional applications in more tumor types. Amgen is further investigating BiTE technology
Press Releases - Amgen Inc.
Nov 8, 2024 · news release 06.05.2024. amgen announces positive results for phase 3 registrational trial evaluating uplizna® (inebilizumab-cdon) for treatment of immunoglobulin g4-related disease (igg4-rd)
AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS …
Oct 6, 2023 · Advances Amgen's Mission to Serve Patients With First-in-Class Rare Disease Medicines. THOUSAND OAKS, Calif., Oct. 6, 2023 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it has completed its acquisition of Horizon Therapeutics plc for $116.50 per share in cash, representing a transaction equity value of approximately $27.8 billion.
AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH
Aug 4, 2022 · THOUSAND OAKS, Calif. and SAN CARLOS, Calif., Aug. 4, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and ChemoCentryx, Inc., (NASDAQ: CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, today announced that the companies have entered into a definitive ...
Newsroom - Amgen
Amgen is committed to providing the media with timely and accurate information. This section offers key resources for journalists, editors and other media professionals. Latest Press Releases
AMGEN OUTLINES GROWTH STRATEGY THROUGH 2030 AT …
Feb 8, 2022 · Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2021, Amgen was named one of the 25 World's Best Workplaces™ by Fortune and Great Place to Work™ and one of the 100 most sustainable companies in the world by Barron's.
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF …
THOUSAND OAKS, Calif., Oct. 20, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ: CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, for …
Amgen | A Worldwide Pioneer in Biotechnology
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics.
AMGEN PRESENTS NEW SCIENTIFIC AND CLINICAL RESEARCH …
Jun 1, 2023 · Amgen is currently investigating tarlatamab in multiple trials, including DeLLphi-301, a potentially registrational Phase 2 study in heavily pretreated SCLC. The DeLLphi-304 trial is a Phase 3 study comparing tarlatamab with standard of care chemotherapy in second-line treatment of SCLC. About Amgen Oncology